Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7896.042 | 0.9968 | 0.9945 | 1.1632 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7896.042 | 1.0266 | 1.0456 | 1.1632 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7896.042 | 0.9973 | 0.9953 | 1.1632 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7896.042 | 1.1054 | 1.1799 | 1.1632 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7896.042 | 1.0135 | 1.0232 | 1.1632 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7896.042 | 1.0530 | 1.0908 | 1.1632 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7896.042 | 0.9847 | 0.9737 | 1.1632 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9648.026 | 1.0243 | 1.0691 | 0.7065 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9648.026 | 1.0114 | 1.0323 | 0.7065 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9648.026 | 0.9983 | 0.9951 | 0.7065 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9648.026 | 0.9997 | 0.9993 | 0.7065 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9648.026 | 1.0303 | 1.0864 | 0.7065 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9648.026 | 1.0188 | 1.0533 | 0.7065 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9648.026 | 1.0393 | 1.1121 | 0.7065 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9648.026 | 1.0162 | 1.0461 | 0.7065 | |
MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9648.026 | 0.9958 | 0.9880 | 0.7065 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7897.018 | 0.9752 | 0.9413 | 0.8448 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7897.018 | 0.9467 | 0.8745 | 0.8448 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7897.018 | 0.9673 | 0.9229 | 0.8448 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7897.018 | 0.9460 | 0.8727 | 0.8448 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7897.018 | 0.9542 | 0.8921 | 0.8448 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7897.018 | 0.9983 | 0.9961 | 0.8448 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7897.018 | 0.9824 | 0.9584 | 0.8448 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7897.018 | 0.9907 | 0.9779 | 0.8448 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7897.018 | 0.9410 | 0.8611 | 0.8448 |